EFFECT OF NON-SELECTIVE BETA BLOCKERS ON ESOPHAGEAL VARICES AND PORTAL VEIN DIAMETER IN CIRRHOTIC HCV PATIENTS
Abstract
ABSTRACT
Background: Esophageal varices is one of the major complications of portal hypertension and one
of the main causes of death in cirrhotic patients, so prophylaxis from esophageal varices bleeding
can decrease the number of deaths in those patients.
Aim of the work: To assess the effect of non-selective beta blockers on portal vein diameter and
grades of esophageal varices.
Subjects and methods: Our study was carried out at Gastroenterology and Hepatology unit,
Internal Medicine department, Zagazig University hospital. Forty patients with HCV positive liver
cirrhosis were enclosed in the study. All were Child Pugh grade A and B, diagnosed by clinical
examination, laboratory investigations (hepatitis C virus antibody, hepatitis C virus RNA by
polymerase chain reaction, hepatitis B virus surface antigen, liver and kidney functions, complete
blood count, INR and alpha feto-protein) and pelvi-abdominal ultrasound findings. Upper gastrointestinal (GI) endoscopy was done at the beginning of the study for detection and grading of
esophageal varices (EVs) and those without EVs were excluded, also portal vein diameter (PVD)
was recorded by ultrasound. The maximum tolerated dose of Propranolol (decrease pulse rate by
25% but not below 60 beats per minute) was given to all patients for three months. EVs grading, by
upper GI endoscopy, and PVD were reassessed at the end of the study.
Results: Propranolol showed a significant reduction in heart rate and PVD for the pre and posttreatment results after three months of treatment (P<0.001 for both). The dose of Propranolol didn't
show significant effect on reduction of small size EVs (P=0.07) while the percent of reduction of
PVD correlated significantly with percent of reduction in EVs grade for the pre and post-treatment
(P<0.05). A cut off point for detection of significant EVs (GII and III) was 12.5 mm with
sensitivity 82.4%, specificity 47.8%, positive predictive value (PPV) 53.8% and negative predictive
value (NPV) 78.6%.
Conclusion: Non-selective beta blocker (Propranolol) caused significant reduction in portal vein
diameter and the percentage of reduction of portal vein diameter significantly correlated with
change in esophageal varices grades.
Key words: Portal hypertension, HCV, Esophageal varices, Portal vein diameter, liver cirrhosis and
Non-selective beta blockers.
Background: Esophageal varices is one of the major complications of portal hypertension and one
of the main causes of death in cirrhotic patients, so prophylaxis from esophageal varices bleeding
can decrease the number of deaths in those patients.
Aim of the work: To assess the effect of non-selective beta blockers on portal vein diameter and
grades of esophageal varices.
Subjects and methods: Our study was carried out at Gastroenterology and Hepatology unit,
Internal Medicine department, Zagazig University hospital. Forty patients with HCV positive liver
cirrhosis were enclosed in the study. All were Child Pugh grade A and B, diagnosed by clinical
examination, laboratory investigations (hepatitis C virus antibody, hepatitis C virus RNA by
polymerase chain reaction, hepatitis B virus surface antigen, liver and kidney functions, complete
blood count, INR and alpha feto-protein) and pelvi-abdominal ultrasound findings. Upper gastrointestinal (GI) endoscopy was done at the beginning of the study for detection and grading of
esophageal varices (EVs) and those without EVs were excluded, also portal vein diameter (PVD)
was recorded by ultrasound. The maximum tolerated dose of Propranolol (decrease pulse rate by
25% but not below 60 beats per minute) was given to all patients for three months. EVs grading, by
upper GI endoscopy, and PVD were reassessed at the end of the study.
Results: Propranolol showed a significant reduction in heart rate and PVD for the pre and posttreatment results after three months of treatment (P<0.001 for both). The dose of Propranolol didn't
show significant effect on reduction of small size EVs (P=0.07) while the percent of reduction of
PVD correlated significantly with percent of reduction in EVs grade for the pre and post-treatment
(P<0.05). A cut off point for detection of significant EVs (GII and III) was 12.5 mm with
sensitivity 82.4%, specificity 47.8%, positive predictive value (PPV) 53.8% and negative predictive
value (NPV) 78.6%.
Conclusion: Non-selective beta blocker (Propranolol) caused significant reduction in portal vein
diameter and the percentage of reduction of portal vein diameter significantly correlated with
change in esophageal varices grades.
Key words: Portal hypertension, HCV, Esophageal varices, Portal vein diameter, liver cirrhosis and
Non-selective beta blockers.
Full Text:
PDFRefbacks
- There are currently no refbacks.